US biopharmaceutical firm Amgen said Monday it has reached agreement to acquire Horizon Therapeutics, which specializes in medicine for rare and auto-immune diseases, for $27.8 billion.
This article was originally published on this website.
US biopharma firm Amgen to acquire Horizon Therapeutics for $28 bn
